ONESOURCE · Healthcare
Onesource Specialty Pharma Ltd. reported revenue of ₹290 cr for October to December 2025, −26.2% on the year and −22.9% on the quarter. Over the last four quarters revenue comes to ₹1,419 cr, +29.9% on the four before.
Operating profit (EBITDA) was ₹17.0 cr, a margin of 5.9%, −3,027 bps on the year and −2,233 bps on the quarter. Over the last 8 quarters the margin has ranged from −4.1% to 43.0%, averaging 22.6%. Operating costs grew +8.8%, faster than revenue at −26.2%, so operating profit grew less than sales.
The net loss was ₹89.0 cr, with earnings per share of −₹7.74.
On earnings per share of ₹1.77 over the last four quarters, the stock at ₹1,408.00 trades at 795.5 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow, the auditor's review, segment results, one-off items line by line and what management said on the call.
Operating margin fell sharply on the year. Pricing, input costs, or mix?
EBITDA margin 5.9%, −3,027 bps on the year (−2,233 bps on the quarter).
Source: Quarterly statements
Could not run on this quarter: Headline vs core profit, Other income carrying profit, Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
| Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹56.0 cr | ₹73.0 cr | ₹292 cr | ₹334 cr | ₹393 cr | ₹426 cr | ₹327 cr | ₹376 cr | ₹290 cr | ₹428 cr | ₹449 cr | ₹516 cr |
| YoY | — | — | — | +882% | +602% | +484% | +12% | +13% | −26% | +0% | +37% | +37% |
| EBITDA margin | −17.9% | −4.1% | 21.9% | 23.1% | 36.1% | 43.0% | 26.9% | 28.2% | 5.9% | 21.5% | 27.4% | 31.6% |
| Other income, % of PBT | — | — | — | — | — | 2% | — | 50% | — | — | 0% | −2% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | — | — | — | — | — | −19% | — | — | — | — | −23% | −9% |
| Net profit | −₹130 cr | −₹40.0 cr | −₹6.0 cr | −₹42.0 cr | −₹69.0 cr | ₹98.0 cr | ₹0.0 cr | ₹10.0 cr | −₹89.0 cr | ₹5.0 cr | ₹25.0 cr | ₹57.0 cr |
| YoY | — | — | — | — | — | — | — | — | — | −95% | — | +470% |
| Core profit YoY | — | — | — | — | — | — | — | — | −437% | −102% | — | +1,700% |
| EPS | — | — | — | — | −₹6.02 | ₹8.61 | −₹0.02 | ₹0.92 | −₹7.74 | ₹0.40 | ₹2.18 | ₹5.01 |
| Flags | · | · | · | 1 | 1 | 2 | ✓ | 2 | 1 | 1 | 1 | 1 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Onesource Specialty Pharma Ltd. reported revenue of ₹290 cr (−26.2% on the year) and net profit of −₹89.0 cr (— on the year) for October to December 2025.
Profit before other income, exceptional items and tax moved −437.0% on the year, against — for reported profit.
1 check raised a question: Operating margin fell sharply on the year. Pricing, input costs, or mix?
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.